Mizuho Securities USA LLC acquired a new stake in Bellevue Life Sciences Acquisition Corp. (NASDAQ:BLAC - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 133,495 shares of the company's stock, valued at approximately $1,388,000. Mizuho Securities USA LLC owned about 1.47% of Bellevue Life Sciences Acquisition as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cowen AND Company LLC bought a new stake in shares of Bellevue Life Sciences Acquisition during the fourth quarter valued at approximately $165,000. Robinson Capital Management LLC bought a new stake in Bellevue Life Sciences Acquisition during the 3rd quarter valued at $438,000. Wealthspring Capital LLC boosted its position in Bellevue Life Sciences Acquisition by 335.7% during the 4th quarter. Wealthspring Capital LLC now owns 87,579 shares of the company's stock worth $920,000 after acquiring an additional 67,479 shares during the period. Schechter Investment Advisors LLC grew its stake in shares of Bellevue Life Sciences Acquisition by 277.2% in the third quarter. Schechter Investment Advisors LLC now owns 114,711 shares of the company's stock worth $1,193,000 after purchasing an additional 84,300 shares in the last quarter. Finally, Wolverine Asset Management LLC increased its holdings in shares of Bellevue Life Sciences Acquisition by 40.6% during the third quarter. Wolverine Asset Management LLC now owns 173,110 shares of the company's stock valued at $1,800,000 after purchasing an additional 50,000 shares during the period. 55.30% of the stock is owned by institutional investors and hedge funds.
Bellevue Life Sciences Acquisition Price Performance
Shares of NASDAQ BLAC remained flat at $10.80 during midday trading on Friday. 1 shares of the company were exchanged, compared to its average volume of 28,086. The stock's 50 day moving average is $10.70 and its 200-day moving average is $10.59. Bellevue Life Sciences Acquisition Corp. has a fifty-two week low of $10.17 and a fifty-two week high of $11.60.
About Bellevue Life Sciences Acquisition
(
Free Report)
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bellevue Life Sciences Acquisition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bellevue Life Sciences Acquisition wasn't on the list.
While Bellevue Life Sciences Acquisition currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
